ETFs positioned on Roche Holding AG

Name Weight AuM 1st Jan change Investor Rating
9.03% 121 M€ -.--% -
8.46% 20 M€ +16.14% -
4.67% 2 M€ -.--%
2.85% 6 M€ -.--% -
2.47% 8 M€ +10.37% -
2.05% 10 M€ +6.14% -
1.77% 33 M€ +8.92% -
1.75% 3 M€ +11.67% -
1.69% 6 M€ -.--%
1.59% 29 M€ +8.37% -
1.53% 273 M€ +11.32%
1.40% 177 M€ +10.64%
1.37% 8 M€ +5.35% -
1.23% 12 M€ +15.09% -
1.15% 10 M€ -3.35% -
0.95% 274 M€ +15.64% -
0.94% 216 M€ +14.54% -
0.94% 453 M€ -.--%
0.85% 33,076 M€ +15.79% -
0.84% 276 M€ +11.40% -
0.64% 1,005 M€ +9.07%
0.53% 284 M€ -.--%
0.53% 5 M€ -.--% -
0.51% 23 M€ -.--% -
0.51% 786 M€ -.--%
0.50% 206 M€ -.--%
0.49% 329 M€ +29.62%
0.48% 205 M€ -.--%
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
103,605
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
surperformance-ratings-light-chart ROCHE-HOLDING-AGMore Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
18
Last Close Price
253.80CHF
Average target price
303.36CHF
Spread / Average Target
+19.53%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ROG Stock
  4. ETFs Roche Holding AG